Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 187 results for "Zegerid"

Par Will Pay $100 Million in Zegerid Patent Infringement Suit

Generics firm Par Pharmaceuticals has agreed to pay Salix Pharmaceuticals $100 million to settle a patent infringement lawsuit over its version of Salix's heartburn drug Zegerid. The settlement covers Salix, its subsidiary Santarus and ... FDA News, 4 weeks ago
Salix settles Zegerid patent infringement suit Seeking Alpha, 1 month ago

Par settles patent suit and will pay Salix and MU $100M in fight over Zegerid copy

Generic drugmaker Par Pharmaceutical is throwing in the towel in its long-running fight with Santarus ($SNTS) over its heartburn med Zegerid, and $100 million along with it. It reported today that the payment will settle their back-and-forth patent ...
 FiercePharma1 month ago

Peptic Ulcers - Pipeline Review, H2 2014 - New Market Research Report

Global Markets Direct's, 'Peptic Ulcers - Pipeline Review, H2 2014', provides an overview of the Peptic Ulcers's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peptic Ulcers, complete with ...
 Franklin Credit Management Corporation4 days ago

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd.
 CNBC3 weeks ago PROGENICS PHARMACEUTICALS : FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR┬« Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain  4 Traders3 weeks ago FDA Approves RELISTOR Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain  FirstWord Pharma3 weeks ago FDA Approves RELISTOR(r) Subcutaneous Injection for the Treatment o...  Finwin3 weeks ago
[x]  

PAR PHARMACEUTICAL COMPANIES, INC. FILES (8-K) Disclosing Other Events

Item 8.01. Other Events. On September 22, 2014 (the "Effective Date"), the Company entered into a settlement agreement with Salix Pharmaceuticals, Inc. ("Salix"), Santarus, Inc. ("Santarus") and The Curators of the University of Missouri ...
 Pharmacy Choice1 month ago
People Daily

Ulcer, symptoms and treatment

Share This Tags Ulcers are holes that form in the lining of the upper part of the gastrointestinal (GI) tract. When they occur in the stomach, they are called gastric ulcers. If they form in the first part of your small ...
 People Daily1 month ago

Salix Pharmaceuticals Jumps on Takeover Rumours by Allergan

Salix Pharmaceuticals Ltd. ( SLXP ) shares surged 15.5% after The Wall Street Journal claimed that Allergan Inc. ( AGN ) has approached Salix to acquire it. Salix also touched a 52-week high of $162.38 during the trading session on Aug 19. The ...
 Yahoo! Finance2 months ago

SALIX PHARMACEUTICALS : Updates on Second Quarter Results

Salix Pharmaceuticals reported financial and operating results for the second quarter ended June 30 , and provided other business updates. In an August 7 release, the company noted that key financial highlights include: -Results for the first ...
 4 Traders2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less